

1 John B. Sganga (State Bar No. 116,211)
Frederick S. Berretta (State Bar No. 144,757)
2 Joshua J. Stowell (State Bar No. 246,916)
KNOBBE, MARTENS, OLSON & BEAR, LLP
3 550 West C Street
Suite 1200
4 San Diego, CA 92101
(619) 235-8550
5 (619) 235-0176 (FAX)

6 Vicki S. Veenker (State Bar No. 158,669)
Adam P. Noah (State Bar No. 198,669)
7 SHEARMAN & STERLING LLP
1080 Marsh Road
8 Menlo Park, CA 94025
(650) 838-3600
9 (650) 838-3699 (FAX)

10 Attorneys for Plaintiffs and Counter-Defendants
THE LARYNGEAL MASK COMPANY LTD.
11 and LMA NORTH AMERICA, INC.

12 **IN THE UNITED STATES DISTRICT COURT**
13 **FOR THE SOUTHERN DISTRICT OF CALIFORNIA**

14 THE LARYNGEAL MASK COMPANY
15 LTD. and LMA NORTH AMERICA, INC.,

16 Plaintiffs,

17 v.

18 AMBU A/S, AMBU INC., and AMBU LTD.,

19 Defendants.

) Civil Action No. 07 CV 1988 DMS (NLS)

) **PLAINTIFFS' RESPONSES TO**
) **DEFENDANTS' OBJECTIONS TO**
) **EVIDENCE SUBMITTED BY**
) **PLAINTIFFS IN OPPOSITION TO**
) **AMBU'S THREE PENDING MOTIONS**
) **FOR SUMMARY JUDGMENT**

) **Date: September 18, 2009**

) **Time: 1:30 p.m.**

) **Courtroom 10, 2nd Floor**

) **Honorable Dana M. Sabraw**

22 AMBU A/S, AMBU INC., and AMBU LTD.,

23 Counterclaimants,

24 v.

25 THE LARYNGEAL MASK COMPANY
26 LTD. and LMA NORTH AMERICA, INC.,

27 Counter-Defendants.

) **CONFIDENTIAL PORTIONS**
) **FILED UNDER SEAL**

1 Plaintiffs The Laryngeal Mask Company Ltd. and LMA North America, Inc. (“LMA”
2 or “Plaintiffs”) hereby respond to the objections of Defendants Ambu A/S, Ambu, Inc., and
3 Ambu Ltd. (“Ambu” or “Defendants”) to certain evidence submitted by Plaintiffs in support
4 of LMA’s Oppositions to Ambu’s Motion for Summary Judgment of Invalidity for Lack of
5 Written Description [Dkt. # 295], Motion for Summary Judgment of Invalidity for
6 Anticipation and Obviousness [Dkt. # 296], and Motion for Partial Summary Judgment of
7 Non-Infringement [Dkt. # 297].

8 **A. Declaration of John B. Sganga in Support of Oppositions to Defendants’ Three**
9 **Pending Motions for Summary Judgment**

- 10 1. **Exhibit 8 at 380. Excerpt from *Understanding Anesthesia Equipment***
11 **bearing bates numbers AMBU258105-AMBU258118 (“If the tip fails to**
12 **stay flattened or the cuff begins to roll over, the mask should be removed**
and reinserted...If resistance is felt, the tip may have folded over on
itself.”).

13 Ambu’s Objections

14 Hearsay (Fed. R. Evid. 802). Cited text portions are offered for the truth of the matter
15 asserted and therefore constitute inadmissible hearsay.

16 LMA’s Response

17 This statement is not hearsay because it is not being offered for the truth of the matter
18 asserted, only to show that practitioners believed the mask tip foldover was a possible
19 problem. Also, this is not hearsay under Fed. R. Evid 801(d)(2)(B) because Ambu
20 manifested a belief in the truth of this statement by also recognizing that tip foldover was a
21 significant problem. Ambu promoted the reinforced tip of its new product as [REDACTED]

22 [REDACTED]
23 [REDACTED] Ex. 15. Ambu also prepared
24 brochures touting the reinforced tip as helping to “prevent folds during insertion that can
25 cause improper positioning and possible airway trauma” (Ex. 16), and enabling “fast and
26 accurate positioning” (Ex. 17). This statement may also come under an exception to the
27 hearsay rule under Fed. R. Evid 803(18) because it is found in a published treatise on
28 medicine and may be relied upon by an expert witness at trial. The statement from a medical

1 treatise also has sufficient circumstantial guarantees of trustworthiness so falls under the
2 residual exception of Fed. R. Evid. 807 to the hearsay rule.

3 **2a. Exhibit 14 at 38-39. Excerpts from the May 22, 2009 deposition of Jens**
4 **Frimann of Ambu.**

5 Ambu's Objections

6 Irrelevant (Fed. R. Evid. 402). The exhibit is offered for the proposition that "Ambu
7 began designing its first LM device in 2002." Opp. to 102/103 MSJ at 6. Ambu's early design
8 efforts are irrelevant to the determination of anticipation or obviousness, which is based on
9 the cited prior art references. *See KSR Int'l Co. v. Teleflex Inc.*, 550 U.S. 398, 406-07 (2007).

10 LMA's Response

11 Failed attempts and struggles of others to solve a problem are relevant to a
12 determination of nonobviousness.

13 It is jurisprudentially inappropriate to disregard any relevant evidence on any
14 issue in any case, patent cases included. Thus evidence rising out of the so-
15 called 'secondary considerations' must always when present be considered en
16 route to a determination of obviousness. Indeed, evidence of secondary
17 considerations may often be the most probative and cogent evidence in the
18 record. It may often establish that an invention appearing to have been obvious
19 in light of the prior art was not.

20 *Stratoflex, Inc. v. Aeroquip Corp.*, 713 F.2d 1530, 1538 (Fed. Cir. 1983) (internal citations
21 omitted). Evidence of "long-felt but unresolved need, failure of others, copying, and
22 unexpected results" is relevant to nonobviousness. *Ruiz v. A.B. Chance Co.*, 234 F.3d 654,
23 662-63 (Fed. Cir. 2000); *see also Apple Computer, Inc. v. Articulate Systems, Inc.*, 234 F.3d
24 14, 26 (Fed. Cir. 2000).

25 **2b. Exhibit 14 at 64-65. Excerpts from the May 22, 2009 deposition of Jens**
26 **Frimann of Ambu.**

27 Ambu's Obejctions

28 Irrelevant (Fed. R. Evid. 402). The exhibit is offered for the proposition that "Ambu's
initial approach was to reinforce the entire cuff all the way around the backplate." Opp. to
102/103 MSJ at 6. Ambu's early design efforts are irrelevant to the determination of
anticipation or obviousness which is based on the cited prior art references. *See KSR Int'l Co.*
v. Teleflex Inc., 550 U.S. 398, 406- 07 (2007).

1 LMA's Response

2 See LMA's response to 2a above. Failed attempts and struggles of others to solve a
3 problem are relevant to a determination of nonobviousness. *See In re Piasecki*, 745 F.2d
4 1468, 1475 (Fed. Cir. 1984) (Failure of others to provide a feasible solution to a longstanding
5 problem is probative of non-obviousness.)

6 **2c. Exhibit 14 at 65-66. Excerpts from the May 22, 2009 deposition of Jens**
7 **Frimann of Ambu.**

8 Ambu's Objections

9 Irrelevant (Fed. R. Evid. 402). The exhibit is offered for the proposition that
10 "However, Ambu ultimately rejected this approach because the cuff was too stiff." Opp. to
11 102/103 MSJ at 6. Ambu's early design efforts are irrelevant to the determination of
12 anticipation or obviousness which is based on the cited prior art references. *See KSR Int'l Co.*
13 *v. Teleflex Inc.*, 550 U.S. 398, 406- 07 (2007).

14 LMA's Response

15 See LMA's responses to 2a and 2b above. Failed attempts and struggles of others to
16 solve a problem are relevant to a determination of nonobviousness.

17 **2d. Exhibit 14 at 68. Excerpts from the May 22, 2009 deposition of Jens**
18 **Frimann of Ambu.**

19 Ambu's Objections

20 Irrelevant (Fed. R. Evid. 402). The exhibit is offered for the proposition that [REDACTED]

21 Opp. to 102/103 MSJ at 6. Ambu's early design efforts are irrelevant to the determination of
22 anticipation or obviousness which is based on the cited prior art references. *See KSR Int'l Co.*
23 *v. Teleflex Inc.*, 550 U.S. 398, 406- 07 (2007).

24 LMA's Response

25 See LMA's responses to 2a and 2b above. Failed attempts and struggles of others to
26 solve a problem are relevant to a determination of nonobviousness.

27 ///

28 ///

1 **2e. Exhibit 14 at 73. Excerpts from the May 22, 2009 deposition of Jens**
2 **Frimann of Ambu.**

3 Ambu's Objections

4 Irrelevant (Fed. R. Evid. 402). The exhibit is offered for the proposition that [REDACTED]

5 [REDACTED]
6 [REDACTED]
7 [REDACTED] Opp. to 102/103 MSJ at 6. Ambu's early design efforts are
8 irrelevant to the determination of anticipation or obviousness which is based on the cited prior
9 art references. *See KSR Int'l Co. v. Teleflex Inc.*, 550 U.S. 398, 406-07 (2007).

10 LMA's Response

11 See LMA's responses to 2a and 2b above. Failed attempts and struggles of others to
12 solve a problem are relevant to a determination of nonobviousness.

13 **3. Exhibit 15. Deposition exhibit number 75 used at the May 19, 2009**
14 **deposition of Henrik Wendler of Ambu bearing bates numbers**
15 **AMBU0115837-AMBU0115852.**

16 Ambu's Obejctions

17 Irrelevant (Fed. R. Evid. 402, 403). The exhibit is offered for the proposition that
18 "Ambu promoted the reinforced tip of its new product as a 'unique selling point' because it
19 prevented folding during insertion, a problem it characterized as a 'one of the most common
20 reasons for misplacement.'" Opp. to 102/103 MSJ at 6. Ambu's marketing practices are
21 irrelevant to the determination of obviousness. The Court has already determined that the
22 laryngeal mask airway products referenced in this exhibit *do not infringe the patent-in-suit*.
23 *See* Dkt. No. 224. They are therefore irrelevant to show the commercial success of the
24 patented product, copying behavior by others, or any other secondary consideration of
25 nonobviousness. *See Ormco Corp. v. Align Tech., Inc.*, 463 F.3d 1299, 1311-12 (Fed. Cir.
26 2006) ("Evidence of commercial success, or other secondary considerations, is only
27 significant if there is a nexus between the claimed invention and the commercial success.").
28 Furthermore, the document is dated February 20, 2009 and is therefore irrelevant to show
Ambu's 2004-2005 marketing messaging.

1 LMA's Response

2 Ambu's recognition of the importance of the invention and praise for the invention are
3 relevant to a determination of nonobviousness. *Gambro Lundia AB v. Baxter Healthcare*
4 *Corp.*, 110 F.3d 1573, 1579 (Fed. Cir. 1997) ("[The accused infringer's] recognition of the
5 importance of this advance is relevant to the determination of nonobviousness."); *Libbey-*
6 *Owens-Ford Co. v. BOC Group Inc.*, 655 F. Supp. 897, 914 (D.N.J. 1987) ("[S]tatements of
7 praise by the [accused infringer] made prior to the initiation of litigation are strong indication
8 of the non-obviousness of [the] invention."). Ambu's accused products use the claimed cuff
9 reinforcement so the nexus to commercial success is established despite lack of a "tube joint."
10 *Syntex (U.S.A.) Inc. v. Paragon Optical Inc.*, 7 USPQ2d 1001, 1005 (D. Ariz. 1987)
11 ("Commercial success of an invention is measured by the sales of the infringers as well as the
12 sale by [patentee]."). Also, the AuraFlex has not been determined to be non-infringing and
13 also uses the claimed invention. Also, [REDACTED]
14 [REDACTED] (AMBU0115837). It was printed from a native file on February
15 20, 2009 which is why that date also appears in the footer.

16 **4. Exhibit 16. Piece of Ambu marketing literature entitled "Ambu Laryngeal**
17 **Mask" bearing bates number LMA00105743 (color highlighting added).**

18 Ambu's Objections

19 Irrelevant (Fed. R. Evid. 402, 403). The exhibit is offered for the propositions that
20 "Ambu also prepared brochures touting the reinforced tip as helping to 'prevent folds during
21 insertion that can cause improper positioning and possible airway trauma,'" and "Ambu also
22 emphasized that the reinforced cuff tip enabled it to use a thinner and softer cuff which forms
23 a better seal." Opp. to 102/103 MSJ at 6. Ambu's marketing practices are irrelevant to the
24 determination of obviousness. The Court has already determined that the laryngeal mask
25 airway products referenced in this exhibit *do not infringe the patent-in-suit*. See Dkt. No. 224.
26 They are therefore irrelevant to show the commercial success of the patented product,
27 copying behavior by others, or any other secondary consideration of nonobviousness. See
28 *Ormco Corp. v. Align Tech., Inc.*, 463 F.3d 1299, 1311-12 (Fed. Cir. 2006) ("Evidence of

1 commercial success, or other secondary considerations, is only significant if there is a nexus
2 between the claimed invention and the commercial success.”).

3 LMA’s Response

4 See LMA’s response to 3 above. Ambu’s recognition of the importance of the
5 invention and praise for the invention are relevant to a determination of nonobviousness.

6 **5. Exhibit 17. “Ambu AuraFlex Brochure” downloaded from the Ambu**
7 **website on May 28, 2009.**

8 Ambu’s Objections

9 Irrelevant (Fed. R. Evid. 402, 403). The exhibit is offered for the proposition that
10 “Ambu also prepared brochures touting the reinforced tip as...enabling ‘fast and accurate
11 positioning.’” Opp. to 102/103 MSJ at 6. LMA has failed to show that the commercial
12 success of the remaining accused Flex product is either substantial or the result of the
13 patented invention. (Dkt. # 294-3 at Ex. 2, Rebuttal Expert Report of Ryan Sullivan at 8, 10.)
14 Nor is this relevant to any other secondary consideration of nonobviousness. *See Ormco*
15 *Corp. v. Align Tech., Inc.*, 463 F.3d 1299, 1311-12 (Fed. Cir. 2006) (“Evidence of
16 commercial success, or other secondary considerations, is only significant if there is a nexus
17 between the claimed invention and the commercial success.”). Furthermore, the document
18 reflects the state of Ambu’s website on May 28, 2009 and is therefore irrelevant to show
19 Ambu’s 2004- 2005 marketing messaging.

20 LMA’s Response

21 See LMA’s response to 3 above. Ambu’s recognition of the importance of the
22 invention and praise for the invention are relevant to a determination of nonobviousness.

23 **6. Exhibit 18. Expert Report of Creighton Hoffman Regarding Damages**
24 **dated June 19, 2009.**

25 Ambu’s Objections

26 Irrelevant (Fed. R. Evid. 402, 403). The exhibit is offered for the propositions that
27 [REDACTED] and
28 “Competitors...have extensive marketing capacity and ample capital available to pursue a

1 greater share of the laryngeal mask market...none has achieved anything even close to a 10%
2 share of the market.” Opp. to 102/103 MSJ at 6, 25. Ambu’s market share is irrelevant to the
3 determination of obviousness. The vast majority of revenue and market share represent sales
4 of laryngeal mask airway products that the Court has already determined *do not infringe the*
5 *patent-in-suit*. See Dkt. No. 224. Further, LMA has failed to show that the commercial
6 success of the remaining accused Flex product is either substantial or the result of the
7 patented invention. (Dkt. # 294-3 at Ex. 2, Rebuttal Expert Report of Ryan Sullivan at 8, 10.)
8 Nor is this relevant to any other secondary consideration of nonobviousness. See *Ormco*
9 *Corp. v. Align Tech., Inc.*, 463 F.3d 1299, 1311-12 (Fed. Cir. 2006) (“Evidence of
10 commercial success, or other secondary considerations, is only significant if there is a nexus
11 between the claimed invention and the commercial success.”).

12 LMA’s Response

13 See LMA’s response to 3 above. “The commercial response to an invention is
14 significant to determinations of obviousness, and is entitled to fair weight.” *Demaco Corp. v.*
15 *F. Von Langsdorff Licensing Ltd.*, 851 F.2d 1387, 1391 (Fed. Cir. 1988). Ambu’s accused
16 products use the claimed cuff reinforcement so the nexus to commercial success is
17 established despite lack of a “tube joint.” Also, the AuraFlex has not been determined to be
18 non-infringing and also uses claimed invention. The sales numbers are sourced from Ambu’s
19 own document. Market share information was sourced from Ambu’s own document and
20 testimony of an Ambu employee.

21 **7. Exhibit 19. Ambu’s May 7, 2009 company announcement no. 6-2008/09**
22 **entitled “Interim report for Q2 and Q1-Q2 2008/09 (1 October 2008 – 31 March**
23 **2009).”**

24 Ambu’s Obejctions

25 Irrelevant (Fed. R. Evid. 402, 403). The exhibit is offered for the proposition that
26 “Ambu decided to remove the reinforcement from the cuff tip to avoid liability.” Opp. to
27 102/103 MSJ at 7. LMA has not accused the “tipless” version of this product as infringing,
28 the Court has already determined that all but one of Ambu’s products *do not infringe the*
patent-in-suit. See Dkt. No. 224. Further, LMA has failed to show that the commercial

1 success of the remaining accused Flex product is either substantial or the result of the
2 patented invention. (Dkt. # 294-3 at Ex. 2, Rebuttal Expert Report of Ryan Sullivan at 8, 10.)
3 Nor is this relevant to any other secondary consideration of nonobviousness. *See Ormco*
4 *Corp. v. Align Tech., Inc.*, 463 F.3d 1299, 1311-12 (Fed. Cir. 2006) (“Evidence of
5 commercial success, or other secondary considerations, is only significant if there is a nexus
6 between the claimed invention and the commercial success.”).

7 LMA’s Response

8 See LMA’s responses to 3 and 6 above. [REDACTED]

9 [REDACTED] shows that even
10 Ambu believed the reinforced tip was an important selling feature as touted by Ambu’s
11 original sales literature. This form of continued recognition and praise for the invention is
12 relevant to nonobviousness.

13 **8. Exhibit 20. Deposition exhibit number 417 used at the June 12, 2009**
14 **deposition of Allan Jensen of Ambu bearing bates number AMBU0083692-**
AMBU0083694.

15 Ambu’s Objections

16 Irrelevant (Fed. R. Evid. 402, 403). The exhibit is offered for the proposition that
17 “Ambu decided to remove the reinforcement from the cuff tip to avoid liability.” Opp. to
18 102/103 MSJ at 7. LMA has not accused the “tipless” version of this product as infringing.
19 The Court has already determined that all but one of Ambu’s products *do not infringe the*
20 *patent-in-suit*. See Dkt. No. 224. Further, LMA has failed to show that the commercial
21 success of the remaining accused Flex product is either substantial or the result of the
22 patented invention. (Dkt. # 294-3 at Ex. 2, Rebuttal Expert Report of Ryan Sullivan at 8, 10.)
23 Nor is this relevant to any other secondary consideration of nonobviousness. *See Ormco*
24 *Corp. v. Align Tech., Inc.*, 463 F.3d 1299, 1311-12 (Fed. Cir. 2006) (“Evidence of
25 commercial success, or other secondary considerations, is only significant if there is a nexus
26 between the claimed invention and the commercial success.”).

27 LMA’s Response

28 See LMA’s responses to 3 and 6 above.

1 **9. Exhibit 21. Deposition exhibit number 418 used at the June 12, 2009**
2 **deposition of Allan Jensen of Ambu bearing bates numbers AMBU0101669-**
3 **AMBU0101670.**

4 Ambu's Objections

5 Irrelevant (Fed. R. Evid. 402, 403). The exhibit is offered for the proposition that
6 "Ambu deliberately hid the design change from its customers, instructing its sales force that
7 'they are not to alert their customers' to the removal of the tip." Opp. to 102/103 MSJ at 7.
8 LMA has not accused the "tipless" version of this product as infringing. The Court has
9 already determined that all but one of Ambu's products *do not infringe the patent-in-suit*. See
10 Dkt. No. 224. Further, LMA has failed to show that the commercial success of the remaining
11 accused Flex product is either substantial or the result of the patented invention. (Dkt. # 294-3
12 at Ex. 2, Rebuttal Expert Report of Ryan Sullivan at 8, 10.) Nor is this relevant to any other
13 secondary consideration of nonobviousness. See *Ormco Corp. v. Align Tech., Inc.*, 463 F.3d
14 1299, 1311-12 (Fed. Cir. 2006) ("Evidence of commercial success, or other secondary
15 considerations, is only significant if there is a nexus between the claimed invention and the
16 commercial success."). Furthermore, evidence offered to show that Ambu "hid" design
17 changes in its products is highly prejudicial and has no probative value with respect to any
18 issue raised by the motion.

19 LMA's Response

20 See LMA's response to 7 above. [REDACTED]

21 [REDACTED] shows that even Ambu
22 believed the reinforced tip was an important selling feature as touted by Ambu's original
23 sales literature. This form of continued recognition and praise for the invention is relevant to
24 nonobviousness. Also, [REDACTED] no doubt bad for Ambu,
25 but not "prejudicial," and is highly probative of Ambu's own belief that the claimed invention
26 was important to its customers.

27 ///

28 ///

 ///

1 **10. Exhibit 22. Transcript from the August 5, 2009 deposition of Creighton G.**
2 **Hoffman. a. 316:25-317:9.**

3 Ambu's Objections

4 Irrelevant (Fed. R. Evid. 402, 403). The exhibit is offered for the proposition that
5 “Ambu was so desperate to conceal its design change that it unilaterally filled orders with the
6 new design even when customers placed orders for the old, reinforced design.” Opp. to
7 102/103 MSJ at 7. LMA has not accused the “tipless” version of this product as infringing.
8 The Court has already determined that all but one of Ambu’s products *do not infringe the*
9 *patent-in-suit*. See Dkt. No. 224. Further, LMA has failed to show that the commercial
10 success of the remaining accused Flex product is either substantial or the result of the
11 patented invention. (Dkt. # 294-3 at Ex. 2, Rebuttal Expert Report of Ryan Sullivan at 8, 10.)
12 Nor is this relevant to any other secondary consideration of nonobviousness. See *Ormco*
13 *Corp. v. Align Tech., Inc.*, 463 F.3d 1299, 1311-12 (Fed. Cir. 2006) (“Evidence of
14 commercial success, or other secondary considerations, is only significant if there is a nexus
15 between the claimed invention and the commercial success.”). Furthermore, evidence offered
16 to show that Ambu “hid” design changes in its products or forced new models on its
17 customers is highly prejudicial and has no probative value with respect to any issue raised by
18 the motion. Lacks foundation (Fed. R. Evid. 601, 602). The witness is LMA’s *damages*
19 *expert* and Plaintiff has failed to establish he has personal knowledge regarding the alleged
20 Ambu sales practices at issue. To the extent Mr. Hoffman has knowledge, it is based on the
21 statements in the Rebuttal Expert Report of Ryan Sullivan—the deposition exhibit he is
22 testifying about (*see* Ex. 22 at 244:9-15) and is therefore inadmissible hearsay. (Fed. R. Evid.
23 802).

24 LMA's Response

25 See LMA’s responses to 7 and 9 above. Also, there is no doubt from Ambu’s own
26 documents that [REDACTED]. Ex 21 (AMBU0101669-
27 670). Mr. Hoffman had knowledge from his review of Ambu documents and testimony from
28 Ambu witnesses. See Ex. 18 at 5-7.

1 **11. Exhibit 23. Deposition exhibit number 413 used at the June 12, 2009**
2 **deposition of Allan Jensen of Ambu.**

3 Ambu's Objections

4 Irrelevant (Fed. R. Evid. 402, 403). The exhibit is offered for the proposition that
5 "Ambu was undoubtedly reluctant to alert its customers that it had removed a 'key feature' of
6 its laryngeal masks." Opp. to 102/103 MSJ at 7. LMA has not accused the "tipless" version of
7 the products as infringing. The Court has already determined that the products represented in
8 the exhibit *do not infringe the patent-in-suit*. See Dkt. No. 224. Ambu's design changes to its
9 products cannot be offered as evidence of "design-around" efforts, and are not relevant to any
10 other secondary consideration of nonobviousness. See *Ormco Corp. v. Align Tech., Inc.*, 463
11 F.3d 1299, 1311-12 (Fed. Cir. 2006) ("Evidence of commercial success, or other secondary
12 considerations, is only significant if there is a nexus between the claimed invention and the
13 commercial success."). Furthermore, evidence offered to show that Ambu did not reveal
14 design changes in its products or forced new models on its customers is highly prejudicial and
15 has no probative value with respect to any issue raised by the motion.

16 LMA's Response

17 See LMA's responses to 3, 6, 7 and 9 above.

18 **12. Exhibit 24. Deposition exhibit number 374 used at the June 9, 2009**
19 **deposition of Frank Homa of Ambu bearing bates numbers**
20 **AMBU0093132-AMBU0093135.**

21 Ambu's Objections

22 Irrelevant (Fed. R. Evid. 402, 403). The exhibit is offered for the propositions that:

23 [REDACTED]
24 [REDACTED]
25 [REDACTED]
26 [REDACTED]
27 [REDACTED] Opp. to 102/103 MSJ at 7. LMA has not accused

28 the "tipless" version of the products as infringing. The Court has already determined that all
but one of these products *do not infringe the patent-in-suit*. See Dkt. No. 224. Further, LMA

1 has failed to show that the commercial success of the remaining accused Flex product is
2 either substantial or the result of the patented invention. (Dkt. # 294-3 at Ex. 2, Rebuttal
3 Expert Report of Ryan Sullivan at 8, 10.) Nor is this relevant to any other secondary
4 consideration of nonobviousness. *See Ormco Corp. v. Align Tech., Inc.*, 463 F.3d 1299, 1311-
5 12 (Fed. Cir. 2006) (“Evidence of commercial success, or other secondary considerations, is
6 only significant if there is a nexus between the claimed invention and the commercial
7 success.”). Furthermore, evidence offered to show that Ambu’s design changes in its products
8 were unsafe is highly prejudicial and has no probative value with respect to any issue raised
9 by the motion.

10 LMA’s Response

11 See LMA’s responses to 3, 6, 7 and 9 above. Ambu’s inability to design around the
12 claimed invention is relevant to nonobviousness and the lack of noninfringing alternatives
13 (the Court had not yet ruled that certain of Ambu’s products did not infringe because of the
14 “tube joint” limitation). “Evidence of failed attempts of others could be determinative on the
15 issue of obviousness.” *Advanced Display Systems, Inc. v. Kent State University*, 212 F.3d
16 1272, 1285 (Fed. Cir. 2000), *cert. denied*, 532 U.S. 904 (2001). Also, evidence that [REDACTED]
17 [REDACTED] no doubt bad for Ambu, but not “prejudicial,” and is probative
18 of nonobviousness because it shows unexpected results also relevant to nonobviousness. *In*
19 *re Soni*, 54 F.3d 746, 750 (Fed. Cir. 1995).

20 **13. Exhibit 25. Excerpts from the June 12, 2009 deposition of Allan Jensen of**
21 **Ambu at 228:1-5.**

22 Ambu’s Objections

23 Irrelevant (Fed. R. Evid. 402, 403). The exhibit is offered for the proposition that
24 [REDACTED]
25 [REDACTED] Opp.
26 to 102/103 MSJ at 7. LMA has not accused the “tipless” version of the products as infringing.
27 The Court has already determined that all but one of these products *do not infringe the patent-*
28 *in-suit*. See Dkt. No. 224. Further, LMA has failed to show that the commercial success of the

1 remaining accused Flex product is either substantial or the result of the patented invention.
2 (Dkt. # 294-3 at Ex. 2, Rebuttal Expert Report of Ryan Sullivan at 8, 10.) Nor is this relevant
3 to any other secondary consideration of nonobviousness. *See Ormco Corp. v. Align Tech.,*
4 *Inc.*, 463 F.3d 1299, 1311-12 (Fed. Cir. 2006) (“Evidence of commercial success, or other
5 secondary considerations, is only significant if there is a nexus between the claimed invention
6 and the commercial success.”). Furthermore, evidence offered to show that Ambu’s design
7 changes in its products were unsafe is highly prejudicial and has no probative value with
8 respect to any issue raised by the motion. Lacks foundation (Fed. R. Evid. 601, 602). No
9 testimony is introduced to establish what subject or document about which the witness is
10 testifying.

11 LMA’s Response

12 See LMA’s response to 12 above. Also, it is clear from the objected to testimony that
13 [REDACTED]

14 **14. Exhibit 26. Deposition exhibit number 92 used at the May 19, 2009**
15 **deposition of Henrik Wendler of Ambu bearing bates numbers**
AMBU017574-AMBU017577.

16 Ambu’s Objections

17 Irrelevant (Fed. R. Evid. 402, 403). The exhibit is offered for the proposition that
18 [REDACTED]
19 [REDACTED]

20 Opp. to 102/103 MSJ at 7. LMA has not accused the “tipless” version of the products as
21 infringing. The Court has already determined that the products identified in this exhibit *do not*
22 *infringe the patent-in-suit*. See Dkt. No. 224. Ambu’s design changes to its products cannot
23 be offered as evidence of “design-around” efforts, and are not relevant to any other secondary
24 consideration of nonobviousness. *See Ormco Corp. v. Align Tech., Inc.*, 463 F.3d 1299, 1311-
25 12 (Fed. Cir. 2006) (“Evidence of commercial success, or other secondary considerations, is
26 only significant if there is a nexus between the claimed invention and the commercial
27 success.”). Furthermore, evidence offered to show that Ambu’s design changes in its products
28 were dangerous is highly prejudicial and has no probative value with respect to any issue

1 raised by the motion.

2 LMA's Response

3 See LMA's response to 12 above.

4 **15. Exhibit 27. Deposition testimony of Herb D'Alo at 83:20-26.**

5 Ambu's Objections

6 Irrelevant (Fed. R. Evid. 402, 403). The testimony is offered in support of an
7 interpretation of the originally-submitted Figure 10 (see Exhibit 46 below) and to support the
8 proposition that the specification of the '100 discloses a cuff thickener separate from the
9 backplate. The original drawing of Figure 10, and thus any testimony related thereto, is
10 irrelevant because compliance with the written description requirement is based on the
11 specification of the issued patent. *Univ. of Rochester v. G.D. Searle & Co., Inc.*, 358 F.3d
12 916, 927 (Fed. Cir. 2004) (compliance with section 112 is determined by the written
13 description of the issued patent).

14 LMA Response

15 This testimony is relevant to the point that Ambu cannot use the figures in the issued
16 patent to preclude disclosure of the claimed invention on summary judgment because figures
17 in a patent may be imprecise and subject to different interpretations. *Varco, L.P. v. Pason*
18 *Systems USA Corp.*, 436 F.3d 1368, 1375 (Fed. Cir. 2006) ("[The patent's] disclosure and
19 corresponding Figures did not limit the invention."); *Anchor Wall Sys. V. Rockwood*
20 *Retaining Walls, Inc.*, 340 F.3d 1298, 1306-07 (Fed. Cir. 2003) ("the mere fact that the patent
21 drawings depict a particular embodiment of the patent does not operate to limit the claims to
22 that specific configuration.").

23 **16. Exhibit 41. Report of Ryan Sullivan, Ph.D., dated June 19, 2009.**

24 Ambu's Objections

25 Irrelevant (Fed. R. Evid. 402, 403). The exhibit is offered for the proposition that [REDACTED]

26 [REDACTED]
27 [REDACTED] Opp. to 102/103 MSJ at 6.
28 Ambu's market share is irrelevant to the determination of obviousness. The vast majority of

1 revenue and market share represent sales of laryngeal mask airway products that the Court
2 has already determined *do not infringe the patent-in-suit*. See Dkt. No. 224. Further, LMA
3 has failed to show that the commercial success of the remaining accused Flex product is
4 either substantial or the result of the patented invention. (Dkt. # 294-3 at Ex. 2, Rebuttal
5 Expert Report of Ryan Sullivan at 8, 10.) Nor is this relevant to any other secondary
6 consideration of nonobviousness. See *Ormco Corp. v. Align Tech., Inc.*, 463 F.3d 1299, 1311-
7 12 (Fed. Cir. 2006) (“Evidence of commercial success, or other secondary considerations, is
8 only significant if there is a nexus between the claimed invention and the commercial
9 success.”)

10 LMA Response

11 See LMA’s response to 6 above. “The commercial response to an invention is
12 significant to determinations of obviousness, and is entitled to fair weight.” *Demaco Corp. v.*
13 *F. Von Langsdorff Licensing Ltd.*, 851 F.2d 1387, 1391 (Fed. Cir. 1988). Ambu’s accused
14 products use the claimed cuff reinforcement so the nexus to commercial success is
15 established despite lack of a “tube joint.” Also, the AuraFlex has not been determined to be
16 non-infringing and also uses claimed invention.

17 **17. Exhibit 42. Selected Ambu document production bearing bates numbers**
18 **AMBU016563, AMBU138536, AMBU234453, AMBU309204 and**
AMBU309659.

19 Ambu’s Objections

20 Irrelevant (Fed. R. Evid. 402, 403). The exhibit is offered for the proposition that
21 “Ambu’s internal documents reflect positive feedback from clinicians regarding the
22 reinforced cuff tip.” Opp. to 102/103 MSJ at 25. Ambu’s market share is irrelevant to the
23 determination of obviousness. The vast majority of revenue and market share represent sales
24 of laryngeal mask airway products that the Court has already determined *do not infringe the*
25 *patent-in-suit*. See Dkt. No. 224. Further, LMA has failed to show that the commercial
26 success of the remaining accused Flex product is either substantial or the result of the
27 patented invention. (Dkt. # 294-3 at Ex. 2, Rebuttal Expert Report of Ryan Sullivan at 8, 10.)
28 Nor is this relevant to any other secondary consideration of nonobviousness. See *Ormco*

1 *Corp. v. Align Tech., Inc.*, 463 F.3d 1299, 1311-12 (Fed. Cir. 2006) (“Evidence of
2 commercial success, or other secondary considerations, is only significant if there is a nexus
3 between the claimed invention and the commercial success.”).

4 LMA’s Response

5 See LMA’s responses to 6 and 16 above.

6 **18. Exhibit 43. Ambu document production bearing bates numbers**
7 **AMBU247475-AMBU247480.**

8 Ambu’s Objections

9 Irrelevant (Fed. R. Evid. 402, 403). The exhibit is offered for the proposition that
10 “Competitors...have extensive marketing capacity and ample capital available to pursue a
11 greater share of the laryngeal mask market...none has achieved anything even close to a 10%
12 share of the market.” Opp. to 102/103 MSJ at 25. Ambu’s market share is irrelevant to the
13 determination of obviousness. The vast majority of revenue and market share represent sales
14 of laryngeal mask airway products that the Court has already determined *do not infringe the*
15 *patent-in-suit*. See Dkt. No. 224. Further, LMA has failed to show that the commercial
16 success of the remaining accused Flex product is either substantial or the result of the
17 patented invention. (Dkt. # 294-3 at Ex. 2, Rebuttal Expert Report of Ryan Sullivan at 8, 10.)
18 Nor is this relevant to any other secondary consideration of nonobviousness. See *Ormco*
19 *Corp. v. Align Tech., Inc.*, 463 F.3d 1299, 1311-12 (Fed. Cir. 2006) (“Evidence of
20 commercial success, or other secondary considerations, is only significant if there is a nexus
21 between the claimed invention and the commercial success.”).

22 LMA’s Response

23 See LMA’s responses to 6 and 16 above.

24 **19. Exhibit 44. excerpts from the June 3, 2009 deposition of John Schmitz of**
25 **Ambu.**

26 Ambu’s Objections

27 Irrelevant (Fed. R. Evid. 402, 403). The exhibit is offered for the proposition that
28 “[No competitor] has achieved anything even close to a 10% share of the market.” Opp. to
102/103 MSJ at 25. Ambu’s market share is irrelevant to the determination of obviousness.

1 The vast majority of revenue and market share represent sales of laryngeal mask airway
2 products that the Court has already determined *do not infringe the patent-in-suit*. See Dkt. No.
3 224. LMA has also failed to show that the commercial success of the remaining accused Flex
4 product is either substantial or the result of the patented invention. (Dkt. # 294-3 at Ex. 2,
5 Rebuttal Expert Report of Ryan Sullivan at 8, 10.) Nor is this relevant to any other secondary
6 consideration of nonobviousness. See *Ormco Corp. v. Align Tech., Inc.*, 463 F.3d 1299, 1311-
7 12 (Fed. Cir. 2006) (“Evidence of commercial success, or other secondary considerations, is
8 only significant if there is a nexus between the claimed invention and the commercial
9 success.”).

10 LMA’s Response

11 See LMA’s responses to 6 and 16 above.

12 **20. Exhibit 46. Original drawing of Figure 10 of the ‘100 patent.**

13 Ambu’s Objections

14 Irrelevant (Fed. R. Evid. 402, 403). The exhibit is offered for the proposition that the
15 specification of the ‘100 discloses a cuff thickener separate from the backplate. The original
16 drawing of Figure 10 is irrelevant because compliance with the written description
17 requirement is based on the specification of the issued patent. *Univ. of Rochester v. G.D.*
18 *Searle & Co., Inc.*, 358 F.3d 916, 927 (Fed. Cir. 2004) (compliance with section 112 is
19 determined by the written description of the issued patent).

20 LMA’s Response

21 See LMA’s response to 15 above.

22 **21. Exhibit 47. Drawing of Figure 4 of a British patent application.**

23 Ambu’s Objections

24 Irrelevant (Fed. R. Evid. 402, 403). The exhibit is offered for the proposition that the
25 specification of the ‘100 discloses a cuff thickener separate from the backplate. The drawing
26 of Figure 4 from a foreign patent application is irrelevant because compliance with the
27 written description requirement is based on the specification of the issued ‘100 patent, not on
28 extrinsic evidence in the form of foreign patent applications. *Univ. of Rochester v. G.D.*

1 *Searle & Co., Inc.*, 358 F.3d at 927 (compliance with section 112 is determined by the written
2 description of the issued patent).

3 LMA's Response

4 See LMA's response to 15 above.

5 **22. Exhibit 48. Ambu document production bearing bates number**
6 **AMBU002108-2113. Images of Ambu's devices in Opposition to MSJ of**
Invalidity for Lack of Written Description.

7 Ambu's Objections

8 Irrelevant (Fed. R. Evid. 402, 403). The document is misquoted in LMA's brief.

9 Opp. to Written Descrip. MSJ at 16 (emphasis in original): "Our unique reinforced tip
10 has been redesigned and the new tip has gone through a full technical and clinical evaluation.
11 **The reinforced tip prevents foldover during insertion.**"

12 Ex. 48 at AMBU002111: "Our unique reinforced tip has been redesigned and the new
13 tip has gone through a full technical and clinical evaluation. The reinforced tip prevents folds
14 during insertion."

15 The evidence pertaining to Ambu's devices is further irrelevant because extrinsic of devices
16 developed years after the filing of the application of the '100 patent. *Univ. of Rochester v.*
17 *G.D. Searle & Co., Inc.*, 358 F.3d 916, 927 (Fed. Cir. 2004) (compliance with section 112 is
18 determined by the written description of the issued patent).

19 LMA Response

20 LMA agrees that the correct quote is "The reinforced tip prevents **folds** during
21 insertion," but this typographical error does not alter the point that, with or without a gap
22 between the reinforcement and the backplate, the goal of the invention to prevent the tip from
23 folding during insertion is still achieved. LMA's argument was responding to an argument
24 by Ambu and its expert witness Dr. Lampotang.

25 ///

26 ///

27 ///

28 ///

1 **23. Exhibit 49. Excerpts from the May 20, 2009 deposition of Lasse Petersen**
2 **of Ambu. a. 117:11-119:3; 139:24-140:18**

3 Ambu's Objections

4 Irrelevant (Fed. R. Evid. 402). The cited testimony fails to support the propositions for
5 which it is cited. *See* Opp. to Non- Infringement MSJ at 9 (discussing “foldover”). Lacks
6 foundation (Fed. R. Evid. 601, 602). Plaintiffs fail to introduce evidence that the witness has
7 personal knowledge regarding whether Ambu's prototype devices prevented “foldover.” The
8 questioning at 139:24-140:5 is vague and ambiguous.

9 LMA's Response

10 The witness testified that [REDACTED]
11 [REDACTED]
12 [REDACTED]
13 [REDACTED]

14 **24. Exhibit 52. Ambu AuraOnce Datasheet.**

15 Ambu's Objections

16 Irrelevant (Fed. R. Evid. 402, 403). The exhibit is offered for the proposition that
17 “there is no debate that Ambu prominently featured the reinforced tip in its sales literature.”
18 Opp. to 102/103 MSJ at 25. Ambu's marketing practices are irrelevant to the determination of
19 obviousness. The Court has already determined that the laryngeal mask airway product
20 referenced in this exhibit *does not infringe the patent-in-suit*. *See* Dkt. No. 224. They are
21 therefore irrelevant to show the commercial success of the patented product, copying
22 behavior by others, or any other secondary consideration of nonobviousness. *See Ormco*
23 *Corp. v. Align Tech., Inc.*, 463 F.3d 1299, 1311-12 (Fed. Cir. 2006) (“Evidence of
24 commercial success, or other secondary considerations, is only significant if there is a nexus
25 between the claimed invention and the commercial success.”).

26 LMA's Response

27 See LMA's responses to 6 and 16 above.

28 ///

1 **25. Exhibit 54. Excerpts from the May 19, 2009 Deposition of Henrik**
2 **Wendler of Ambu.**

3 Ambu's Objections

4 Irrelevant (Fed. R. Evid. 402, 403). The exhibit is offered for the proposition that
5 "Ambu finally launched its first commercial product in 2004." Opp. to 102/103 MSJ at 6.
6 Ambu's early design efforts are irrelevant to the determination of anticipation or obviousness.

7 LMA's Response

8 See LMA's responses to 2 and 3 above.

9 **26. Exhibit 55. Ambu document production bearing bates number**
10 **AMBU006325.**

11 Ambu's Objections

12 Irrelevant (Fed. R. Evid. 402, 403). The exhibit is offered for the proposition that [REDACTED]

13 [REDACTED] Opp. to 102/103 MSJ at 6.
14 Ambu's market share is irrelevant to the determination of obviousness. The vast majority of
15 revenue and market share represent sales of laryngeal mask airway products that the Court
16 has already determined *do not infringe the patent-in-suit*. See Dkt. No. 224. LMA has also
17 failed to show that the commercial success of the remaining accused Flex product is either
18 substantial or the result of the patented invention. (Dkt. # 294-3 at Ex. 2, Rebuttal Expert
19 Report of Ryan Sullivan at 8, 10.) Nor is this relevant to any other secondary consideration of
20 nonobviousness. See *Ormco Corp. v. Align Tech., Inc.*, 463 F.3d 1299, 1311-12 (Fed. Cir.
21 2006) ("Evidence of commercial success, or other secondary considerations, is only
22 significant if there is a nexus between the claimed invention and the commercial success.").

23 LMA's Response

24 See LMA's responses to 6 and 16 above.

25 ///

26 ///

27 ///

28 ///

1 **B. Declaration of Dihlan Kaylon, Ph.D. in Support of Plaintiffs' Opposition to**
2 **Motion for Partial Summary Judgment of Non-Infringement**

- 3 1. **Kalyon Declaration, ¶ 12: “An additional question is whether the**
4 **stiffener/reinforcement is “narrow.” The AuraFlex™ device stiffener is**
5 **shaped much like a human rib, and is relatively narrow when measured**
6 **in a variety of ways. . .”**

7 Ambu's Objections

8 Improper Expert Opinion. (Fed. R. Evid. 702.) An expert's testimony must be (1)
9 based upon sufficient facts or data, (2) the product of reliable principles and methods, and (3)
10 demonstrate that the witness has applied the principles and methods reliably to the facts of the
11 case. Fed. R. Evid. 702; *Daubert v. Merrell Dow Pharms., Inc.*, 509 U.S. 579, 590-91 (1993).
12 At deposition, Dr. Kaylon testified that he did not understand now the meaning of “narrow”
13 was to be interpreted within the context of the patent:

14 **Q:** So you don't know what narrow is?

15 **A:** I don't know how narrow an object should be to be considered narrow.

16 Kaylon Dep. at 136:2-4. Given that Dr. Kaylon has admitted he does not understand how the
17 term “narrow” is to be understood, his expert opinion applying that concept is inherently
18 unreliable. Further, Dr. Kaylon's declaration does not disclose any reasoning behind the
19 criteria he applies in determining whether the stiffener/reinforcement is “narrow.” As such,
20 his un rebutted deposition testimony that he does not understand how to apply the concept
21 renders his declaration testimony inadmissible.

22 LMA's Response

23 Dr. Kalyon explained in detail in his declaration how he determined that Ambu's rib
24 was narrow by comparing its width to its total arc length, and also by comparing its width to
25 that of the distal region it actually supports during use. Kalyon Decl., ¶¶ 12-14.

26 The snippet of quoted testimony from Dr. Kalyon is taken wholly out of context and
27 apparently has not been submitted by Ambu. *See* Woo Decl, Ex. C. Dr. Kalyon testified as
28 set forth in his declaration that ribs of the aspect ratio found in the Ambu devices are narrow.
 See Appendix A attached hereto (D. Kalyon Tr.) at 86-90, 129, 133 (stating generally that

1 aspect ratios of 10% to 20% would in his opinion be narrow). He only testified that as the
2 length and width of a hypothetical rib begin to approach each other he would not know the
3 limit of whether it could still be considered narrow. *Id.* at 134-136 (stating that it would be
4 difficult to say whether an object with an aspect ratio over 60% could be considered narrow).
5 That hypothetical limit is not relevant to the question of whether Ambu's actual products
6 infringe for the reasons set forth in Dr. Kalyon's Declaration.

7 **2. Kalyon Declaration, ¶ 13: "The stiffener is also 'narrow' when compared**
8 **to the width of the distal region it actually supports during use..."**

9 Ambu's Objections

10 Improper Expert Opinion. (Fed. R. Evid. 702.) Dr. Kaylon continues to opine on
11 whether the accused device meets the claim limitation with respect to narrowness. This
12 testimony is inadmissible for the same reasons discussed in the above objection to ¶ 12.

13 LMA's Response

14 See LMA's response to B.1 directly above.

15 **3. Kalyon Declaration, ¶ 14: "A comparison of the width of the stiffener to**
16 **the width of the posterior surface of the cuff as a whole points to the same**
17 **conclusion..."**

18 Ambu's Objections

19 Improper Expert Opinion. (Fed. R. Evid. 702.) Dr. Kaylon continues to opine on
20 whether the accused device meets the claim limitation with respect to narrowness. This
21 testimony is inadmissible for the same reasons discussed in the above objection to ¶ 12.

22 LMA's Response

23 See LMA's response to B.1 directly above.

24 **C. Declaration of Dr. Archibald Brain in Support of Plaintiffs' Opposition to**
25 **Motion for Summary Judgment of Invalidity for Anticipation and Obviousness**

26 **1. Brain Declaration, ¶¶ 7, 9-13.**

27 Ambu's Objections

28 Irrelevant (Fed. R. Evid. 402, 403). The declaration paragraphs are irrelevant after-
the-fact testimony by an inventor regarding the meaning of a reference. The Federal Circuit

1 has repeatedly deemed similar self-serving testimony irrelevant in a number of contexts. *See*,
2 *e.g.*, *Solomon v. Kimberly- Clark Corp.*, 216 F.3d 1372, 1379 (Fed. Cir. 2000) (“It is
3 particularly inappropriate to consider inventor testimony obtained in the context of litigation
4 in assessing validity under 35 U.S.C. section 112, paragraph 2, in view of the absence of
5 probative value of such testimony.”); *Markman v. Westview Instruments, Inc.*, 52 F.3d 967,
6 985 (Fed. Cir. 1995) (holding that inventor testimony as to “[t]he subjective intent of the
7 inventor when he used a particular term is of little or no probative weight in determining the
8 scope of a claim (except as documented in the prosecution history)”).

9 LMA’s Response

10 Dr. Brain’s declaration testimony regarding “the Brain 1991 article” (his own article)
11 is relevant and probative of what his own 1991 article describes and discloses to one of skill
12 in the art. He is a fact witness with respect to these matters and obviously possesses first-
13 hand knowledge about his own article. The cases cited by Ambu concern only compliance
14 with claim definiteness (35 U.S.C. § 112, para 2) and claim interpretation. They do not
15 pertain to the author of a prior art reference explaining the work that was done and what the
16 reference discloses. *Markman v. Westview Instruments, Inc.*, 52 F.3d 967 (Fed. Cir. 1995),
17 did not preclude inventor testimony on factual matters and the technology in general:

18 Although in *Markman* this court stated that “the subjective intent of the
19 inventor when he used a particular term is of little or no probative weight in
20 determining the scope of a claim,” this statement does not disqualify the
21 inventor as a witness, or overrule the large body of precedent that recognizes
22 the value of the inventor’s testimony. This court in *Markman* did not hold that
23 the inventor can not explain the technology and what was invented and
24 claimed; the Federal Circuit held only that the inventor can not by later
25 testimony change the invention and the claims from their meaning at the time
the patent was drafted and granted. . . . The testimony of the inventor may also
provide background information, including explanation of the problems that
existed at the time the invention was made and the inventor’s solution to these
problems. . . . Although *Markman* and other precedent caution the court
against creative reconstruction of an invention by interested persons, courts are
not novices in receiving and weighing expertise on both sides of an issue.

26 *Voice Technologies Group, Inc. v. VMC Systems, Inc.*, 164 F.3d 605, 616 (Fed. Cir. 1999).

27 Accordingly, Dr. Brain is a competent fact witness to testify about his own work.

28 ///

1 **D. Conclusion**

2 Based on the reasons and arguments presented herein, the Court is respectfully
3 requested to overrule Ambu's objections to the evidence submitted by LMA in opposition to
4 Ambu's three pending motions for summary judgment.

5
6 Respectfully submitted,

7 KNOBBE, MARTENS, OLSON & BEAR, LLP

8
9 Dated: September 11, 2009

By: s/Frederick S. Berretta

10 John B. Sganga

jsganga@kmob.com

11 Frederick S. Berretta

fred.berretta@kmob.com

12 Joshua J. Stowell

joshua.stowell@kmob.com

13 Attorneys for Plaintiffs

14 THE LARYNGEAL MASK COMPANY LTD.

15 and LMA NORTH AMERICA, INC.

16
17 7785631
18 091009
19
20
21
22
23
24
25
26
27
28

APPENDIX A

IN THE UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF CALIFORNIA

THE LARYNGEAL MASK COMPANY LTD,)	
and LMA NORTH AMERICA, INC.,)	
)	
Plaintiffs,)	
)	
-vs-)	No. 07 CV
)	1988 DMS
AMBU A/S, AMBU INC., and)	(NLS)
AMBU LTD.,)	
)	
Defendants.)	
)	
AMBU A/S, AMBU INC., and AMBU LTD.,)	
)	
Counterclaimants,)	
)	
-vs-)	
)	
THE LARYNGEAL MASK COMPANY LTD)	
and LMA NORTH AMERICA, INC.,)	
)	

VIDEO DEPOSITION OF DILHAN M. KALYON

Tuesday, July 28, 2009

San Diego, California

Reported by:
DEBERA ANNE DORAN
CSR No. 7821

IN THE UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF CALIFORNIA

THE LARYNGEAL MASK COMPANY LTD,)
and LMA NORTH AMERICA, INC.,)
Plaintiffs,)
-vs-) No. 07 CV
1988 DMS
AMBU A/S, AMBU INC., and) (NLS)
AMBU LTD.,)
Defendants.)
AMBU A/S, AMBU INC., and AMBU LTD.,)
Counterclaimants,)
-vs-)
THE LARYNGEAL MASK COMPANY LTD)
and LMA NORTH AMERICA, INC.,)
)

Video Deposition of DILHAN M. KALYON,
taken on behalf of Defendants, at 550
West C Street, Suite 1200, San
Diego, California, beginning at
9:30 a.m. and ending at 3:15 p.m.
on Tuesday, July 28, 2009, before
DEBERA ANNE DORAN, Certified
Shorthand Reporter No. 7821.

1 BY MR. KOHM:

2 Q We'll mark as Exhibit 478 the Rule 26 A2B
3 report. Can you tell me what this is, professor?

4 A It's a report dated -- there's a signature
5 date which is June 19. So it's my report dated June 19,
6 2009.

7 Q This report -- your report, Exhibit 478,
8 does it contain the same opinions that are contained in
9 your declaration?

10 A Yes.

11 Q Does it contain any additional opinions?

12 A No.

13 Q So let me get back to my other question.
14 What other opinions are provided in your declaration and
15 report?

16 A The second area covered is the stiffening of
17 the cuff element at its distal end.

18 Q And what opinion were you asked to provide?

19 A The opinion -- the court had construed the
20 distal rib as narrow. And I guess the general question
21 was whether the Ambu devices were stiffened and thickened
22 at their distal ends and whether this was narrow or not.

23 Q Okay. And what special expertise do you
24 have to provide an opinion on what constitutes something
25 being narrow?

1 A It's a very amorphous area. I don't think
2 you will find two experts who will agree as to what
3 narrow is, especially if they are at the other side of
4 the table. It's a very amorphous term. But, in general,
5 I mean the first thing I did was to look up in the
6 dictionary to see how the Webster or Mirriam, et cetera,
7 defines the word "narrow." And basically, the way the
8 dictionary defines it is a width versus a width of an
9 object to be construed as narrow versus another length.
10 For example, you can talk about a narrow road. The
11 length is long and the width is relatively small in
12 comparison to length. Or you could talk about a narrow
13 table. If you were to, for example, shorten this, there
14 is a certain length, there is a certain width.

15 So it's a comparison of a width of
16 dimension, characteristic dimension with another
17 characteristic dimension. And, again, it's not clear how
18 narrow is an object supposed to be to be narrow. Or how
19 wide an object is supposed to be to be wide.

20 I don't think you will find -- well, yeah.
21 So, in summary, what I am saying is that there doesn't
22 seem to be a subspecialty in narrowness.

23 Q Okay. So are you saying that in the context
24 of the '100 patent it's unclear what constitutes narrow,
25 a narrow stiffener?

1 A There are certain indications as to -- as to
2 what narrow is. I mean that's -- but the hundred -- '100
3 patent does not specify, for example, saying that it has
4 to have such-and-such dimensions to be considered narrow.

5 Q So if you were reading the '100 patent and
6 let's say you also had the court's claim construction in
7 hand and you were trying to figure out what constituted a
8 narrow stiffener, would you be able to do so?

9 A Yes. Basically, that's what I've done.

10 Q Well, you've presented three different
11 possibilities. I guess my question is: Would you
12 understand what the patent is -- excuse me. Would you
13 understand what is meant by a narrow stiffener in the
14 context of the '100 patent?

15 MR. BERRETTA: I guess I'm going to object.

16 It assumes facts not in evidence. You can answer.

17 BY MR. KOHM:

18 Q Let me put it this way. If you read the
19 '100 patent and you read the court's claim construction
20 order, would it be readily apparent to you what a narrow
21 stiffener would be as opposed to a broad stiffener?

22 A Yes. In terms of -- not in terms of numbers
23 per se, but in terms of, for example, being able to
24 compare the width of the stiffener versus other relevant
25 dimensions. I mean this is typically what is done in

1 engineering analysis. You take the relevant
2 characteristic dimension and you compare it with another
3 characteristic dimension. For example, fibers, it would
4 be the length divided by the diameter which would be the
5 aspect ratio, right, which would be important.

6 Q Okay. We're talking about several different
7 issues. When you read the '100 patent and the court's
8 claim construction order, is it readily apparent to
9 you -- let me step back.

10 You said that, in order to determine narrow,
11 you have to compare it to some other structure or some
12 other dimension, whether it's the length of the stiffener
13 or it's in comparison to some other object. Is that
14 correct?

15 A I said the width of the stiffener has to be
16 compared with a relevant dimension in the cuff of the
17 laryngeal mask airway device.

18 Q When you read the '100 patent, is it clear
19 to you what that relevant dimension is?

20 A Are you asking quantitative numbers?

21 Q No. I'm asking that relative dimension,
22 what you used to come up with that relative dimension.
23 Is it clear to you what that is when you read the '100
24 patent?

25 A I mean I guess a general understanding from

1 the preferred aspect that the patent is describing a
2 narrow object, basically the extension of this backplate
3 and the longitudinal direction. Without really
4 specifying how wide that ought to be, but wide enough to
5 do the job. I guess that's probably -- it's like -- I
6 mean you want to stiffen this object, and the stiffening
7 is going to be a function of the geometry. And I am
8 assuming -- well, basically what the patent is teaching
9 is -- it's teaching two different mechanisms of
10 stiffening so that it becomes a successfully stiff distal
11 tip so it wouldn't fold over. So you could -- I'm sorry.
12 Is there another question?

13 Q I'm trying to figure -- we're talking about
14 something being narrow. And you say that, in order to
15 determine what is narrow, it's a comparative analysis.
16 Is that correct? It's comparative to either the length
17 or some other relevant dimension.

18 A Yeah, in my analysis, I took, for example,
19 the length of the stiffener in terms of its arc length.

20 Q Right.

21 A So I took the length and divided it by the
22 arc length which gave one measure. And these were
23 numbers like 10 percent, 12 percent. So we are talking
24 about relatively small numbers. Suggesting to me that
25 the stiffener is narrow.

1 cuff -- I mean the width of the stiffener compared to the
2 width of the airway tube. What must the ratio be in
3 order for the stiffener to be deemed narrow in your view?

4 A There is no quantitative number.

5 Q All right. Thank you.

6 Let's go on to number three then. The
7 perimeter of the cuff approach. Can you explain to me
8 what you're measuring with this approach?

9 A Number three was the width divided by the
10 arc length. Right? Or did I miss it? I'm sorry.
11 Perimeter. You're right. Okay.

12 Q Yeah.

13 A So basically what we are measuring here is
14 the width of this --

15 Q Could we use a cross-section AA? I think
16 this will be useful one here. On Exhibit 16 of Exhibit
17 480. Here, why don't we use a blue pen. That will make
18 it show up a little bit easier. So I understand, the
19 width of the stiffener, I understand what you're
20 measuring there. Explain to me the perimeter of the
21 cuff.

22 A The perimeter is this one.

23 Q Okay. And so is there any sort of -- what
24 ratio of the width of the cuff compared to the width of
25 the perimeter must there be in order for it to constitute

1 narrow in your opinion?

2 A Again, there is no definition.

3 Q There is no definition. So how do you
4 determine what is narrow?

5 A We are going back to -- all the way to the
6 beginning. There's really no standard definition here.

7 Q I'm not asking standard definition. In your
8 opinion, how do you determine whether something is
9 narrow?

10 A Is narrow, okay. So in this particular
11 case, when you look at these numbers, you see numbers
12 like ten percent. For example, you take the width of the
13 stiffener. You divide it by its arc length, which is an
14 inverse of aspect ratio, and the number is like ten
15 percent.

16 Q Okay.

17 A So that says, okay, it's close to zero.
18 Farther away from one. So that to me constitutes a
19 narrow object.

20 Q Where -- what is the threshold between
21 narrow and not narrow? Where would you draw that?

22 A It's a relative term.

23 Q I'm asking you. In your opinion, when does
24 narrow no longer -- I'm sorry. When does the width of
25 the stiffener and compare it ratio to the perimeter no

1 understand the question.

2 BY MR. KOHM:

3 Q All right. You've been retained by LMA to
4 give an opinion as to whether something is narrow or not.
5 Is that correct?

6 A I don't think that was the mission for me to
7 come in and define whether an object is narrow or not.
8 But that became part of the task.

9 Q I'm sorry. Could you please read line three
10 to me?

11 A The remaining question is thus whether the
12 stiffener reinforcement is narrow.

13 Q Okay. So are you answering that question in
14 this paragraph?

15 A I'm trying to, yeah.

16 Q Okay. Can you tell me right now what aspect
17 ratio constitutes being narrow?

18 A I am very comfortable in --

19 Q It's yes or no. Let's start with that. Can
20 you tell me that?

21 A I'm comfortable in saying anything close to
22 point one with divided by either the perimeter or the
23 width divided by the length around point one, I'm very
24 comfortable in saying it's narrow.

25 Q Okay. At what point are you no longer

1 comfortable saying it's narrow?

2 A It's a hypothetical. I'm not going to
3 answer that.

4 Q You have to answer my question, sir.

5 A Well --

6 Q You are under oath and retained as an expert
7 to provide your opinion, and I'm asking you what you
8 understand narrow to be. You can't refuse to answer my
9 question.

10 A But you're asking the same question over and
11 over again.

12 Q Because you won't answer my question. I'm
13 asking you. What do you view to be narrow? If you say
14 you don't know, I'm done. I'll stop asking the question.
15 But until you answer the question --

16 A Okay.

17 Q -- I'm going to keep asking it.

18 A Okay. Anything around point one is --

19 Q Okay. Let's do it this way. Point one is
20 narrow?

21 A Point one is narrow.

22 Q What is point two? Is that narrow or not?

23 A I guess -- you would really need some
24 additional criteria to be able to build this all the way
25 up to one. I mean where do you cut off? Point two, yes,

1 in my mind, that's narrow also.

2 Q Okay. What about point three?

3 A Point three, yeah. I mean clearly point one
4 is narrower than point three. By definition is point
5 three narrow. Yeah, I would say it's narrow.

6 Q What about point four?

7 A It's narrow.

8 Q Point five?

9 A I think it's narrow.

10 Q Point six?

11 A Yeah, where do you draw the line? Where is
12 it sufficiently narrow and how do you define that? With
13 the present set of information that's available, it's a
14 very difficult question to answer. I don't know.

15 Q You don't know the answer?

16 A If point six is narrow sufficiently.

17 Q What about point seven?

18 A If I said point six I cannot answer, I don't
19 know the answer, point seven would be the same thing.

20 Q What about point eight?

21 A Same answer.

22 Q What about point nine?

23 A Same answer.

24 Q Aren't we getting close to one? You said
25 one is not narrow or anything close to one is not narrow.

1 A Yeah, I don't know.

2 Q So you don't know what narrow is?

3 A I don't know how narrow an object should be
4 to be considered narrow.

5 Q Okay. Thank you. Let's move on.

6 A In this context obviously. Whether it's
7 point one or one point zero is clear. But point six
8 versus point 65, it's not clear.

9 Q What aspect ratio would be broad?

10 A By aspect ratio, you mean what? The
11 perimeter divided by --

12 Q The same thing that we've been discussing,
13 the width as compared to some other length. What aspect
14 ratio would constitute being broad?

15 A See, that's -- yeah, I really don't get the
16 question. Because how can a width be greater than the
17 perimeter. I mean what kind of --

18 Q We're not talking about greater --

19 A -- aspect ratio is greater than one, how is
20 the width going to be greater than the perimeter. That's
21 exactly what you asked.

22 Q I'm sorry. I don't believe I asked that.
23 If I did, it was my mistake. What I meant to ask was:
24 What aspect ratio would constitute broad? Assuming it's
25 less than --

CERTIFICATE OF SERVICE

I hereby certify that on September 11, 2009, I caused a redacted version of the foregoing
**PLAINTIFFS' RESPONSES TO DEFENDANTS' OBJECTIONS TO EVIDENCE
SUBMITTED BY PLAINTIFFS IN OPPOSITION TO AMBU'S THREE PENDING
MOTIONS FOR SUMMARY JUDGMENT** to be electronically filed with the Clerk of
the Court using the CM/ECF system which will send electronic notification of such filing to
the applicable registered filing users.

Darryl M. Woo
dwoo@fenwick.com
Patrick E. Premo
ppremo@fenwick.com
Bryan Kohm
bkohm@fenwick.com
FENWICK & WEST LLP
555 California Street, 12th Floor
San Francisco CA 94104
T: 415-875-2300
F: 415-281-1350

Additionally, I hereby certify that on September 11, 2009, I caused an unredacted
version of the foregoing document to be served via E-Mail and U.S. Mail to Defendants'
counsel as listed above.

I declare that I am employed in the office of a member of the bar of this Court at
whose direction the service was made.

Dated: September 11, 2009


Linda Ponce de Leon-Garcia